Cryo-Cell International, Inc. (CCEL) 10-Year Financial Performance & Capital Metrics

CCEL • • Industrial / General

HealthcareHealthcare FacilitiesSpecialized Medical ServicesStem Cell & Biotech Services

AboutCryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Show more

Revenue $32M +2.0%
EBITDA $4M +137.4%
Net Income $402K +104.2%
EPS (Diluted) 0.05 +104.4%
Gross Margin 75.15% +2.9%
EBITDA Margin 12.39% +136.7%
Operating Margin 10.88% +127.7%
Net Margin 1.26% +104.1%
ROE -
ROIC -
Debt/Equity -
Interest Coverage 1.87 +118.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 208.4%
✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Profits declining 29.4% over 5 years
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Dividend payout exceeds 100% of earnings
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.74%

5Y0.11%

3Y3.46%

TTM-0.29%

Profit (Net Income) CAGR

10Y-3.15%

5Y-29.39%

3Y-42.21%

TTM104.48%

EPS CAGR

10Y0%

5Y-28.63%

3Y-41.52%

TTM93.41%

ROCE

10Y Avg19.86%

5Y Avg5.49%

3Y Avg-3.63%

Latest8.34%

Peer Comparison

Stem Cell & Biotech Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CCELCryo-Cell International, Inc.	27.55M	3.42	68.40	2.05%	1.26%		13.09%

Profit & Loss

	Nov 2015	Nov 2016	Nov 2017	Nov 2018	Nov 2019	Nov 2020	Nov 2021	Nov 2022	Nov 2023	Nov 2024
Sales/Revenue+	21.09M	23.13M	25.38M	29.22M	31.82M	31.15M	28.88M	30.34M	31.34M	31.99M
Revenue Growth %	0.05%	0.1%	0.1%	0.15%	0.09%	-0.02%	-0.07%	0.05%	0.03%	0.02%
Cost of Goods Sold+	5.63M	5.77M	6.72M	8.54M	10.04M	9.66M	8.99M	8.79M	8.44M	7.95M
COGS % of Revenue	0.27%	0.25%	0.26%	0.29%	0.32%	0.31%	0.31%	0.29%	0.27%	0.25%
Gross Profit+	15.46M	17.35M	18.66M	20.68M	21.78M	21.49M	19.9M	21.54M	22.9M	24.04M
Gross Margin %	0.73%	0.75%	0.74%	0.71%	0.68%	0.69%	0.69%	0.71%	0.73%	0.75%
Gross Profit Growth %	0.07%	0.12%	0.08%	0.11%	0.05%	-0.01%	-0.07%	0.08%	0.06%	0.05%
Operating Expenses+	12.53M	14.93M	13.65M	15.9M	15.13M	13.83M	15.88M	17.52M	35.26M	20.56M
OpEx % of Revenue	0.59%	0.65%	0.54%	0.54%	0.48%	0.44%	0.55%	0.58%	1.12%	0.64%
Selling, General & Admin	12.39M	14.72M	13.48M	15.63M	14.89M	14.29M	14.63M	15.58M	17.12M	18.52M
SG&A % of Revenue	0.59%	0.64%	0.53%	0.54%	0.47%	0.46%	0.51%	0.51%	0.55%	0.58%
Research & Development	45.78K	53.1K	41.16K	91.84K	30.14K	23.85K	49.87K	384.79K	1.17M	1.24M
R&D % of Revenue	0%	0%	0%	0%	0%	0%	0%	0.01%	0.04%	0.04%
Other Operating Expenses	92.11K	154.67K	131.61K	180.26K	206.24K	-489.53K	1.22M	1.55M	16.92M	794.32K
Operating Income+	2.93M	433.59K	5.01M	5.19M	5.06M	7.66M	4.02M	4.02M	-12.3M	3.48M
Operating Margin %	0.14%	0.02%	0.2%	0.18%	0.16%	0.25%	0.14%	0.13%	-0.39%	0.11%
Operating Income Growth %	0.48%	-0.85%	10.55%	0.04%	-0.02%	0.51%	-0.48%	0%	-4.06%	1.28%
EBITDA+	3.17M	720.24K	5.24M	5.51M	5.46M	8.3M	5.34M	5.83M	-10.59M	3.96M
EBITDA Margin %	0.15%	0.03%	0.21%	0.19%	0.17%	0.27%	0.19%	0.19%	-0.34%	0.12%
EBITDA Growth %	0.35%	-0.77%	6.27%	0.05%	-0.01%	0.52%	-0.36%	0.09%	-2.82%	1.37%
D&A (Non-Cash Add-back)	241.21K	286.65K	230K	317.33K	401.31K	635.98K	1.33M	1.81M	1.71M	483.52K
EBIT	2.25M	-1.53M	4.93M	5.16M	5.09M	6.58M	3.99M	4.84M	-12.13M	939.44K
Net Interest Income+	-1.3M	-947.34K	-1.3M	-1.55M	-1.7M	-1.54M	-1.38M	-1.52M	-1.24M	-1.86M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	1.3M	947.34K	1.3M	1.55M	1.7M	1.54M	1.38M	1.52M	1.24M	1.86M
Other Income/Expense	-1.98M	-2.91M	-1.38M	-1.57M	-1.67M	-2.62M	-1.41M	-705.52K	-1.06M	-676.16K
Pretax Income+	949.52K	-2.48M	3.62M	3.62M	3.39M	5.04M	2.61M	3.32M	-13.36M	2.8M
Pretax Margin %	0.05%	-0.11%	0.14%	0.12%	0.11%	0.16%	0.09%	0.11%	-0.43%	0.09%
Income Tax+	-7.16M	-1.16M	1.31M	4.47M	1.1M	1.41M	527.71K	547.54K	-3.84M	2.4M
Effective Tax Rate %	8.54%	0.53%	0.64%	-0.24%	0.68%	0.72%	0.8%	0.84%	0.71%	0.14%
Net Income+	8.11M	-1.32M	2.32M	-854.82K	2.29M	3.62M	2.08M	2.77M	-9.52M	402.1K
Net Margin %	0.38%	-0.06%	0.09%	-0.03%	0.07%	0.12%	0.07%	0.09%	-0.3%	0.01%
Net Income Growth %	13.64%	-1.16%	2.75%	-1.37%	3.68%	0.58%	-0.43%	0.33%	-4.44%	1.04%
Net Income (Continuing)	8.11M	-1.32M	2.32M	-854.82K	2.29M	3.62M	2.08M	2.77M	-9.52M	402.1K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.83	-0.16	0.30	-0.11	0.27	0.45	0.25	0.33	-1.14	0.05
EPS Growth %	15.6%	-1.19%	2.88%	-1.37%	3.45%	0.67%	-0.44%	0.32%	-4.45%	1.04%
EPS (Basic)	0.85	-0.16	0.33	-0.11	0.29	0.48	0.26	0.33	-1.14	0.05
Diluted Shares Outstanding	9.8M	8.11M	7.65M	7.46M	8.41M	8.14M	8.36M	8.48M	8.34M	8.21M
Basic Shares Outstanding	9.54M	8.11M	7.06M	7.46M	8.41M	8.14M	8.14M	8.47M	8.34M	8.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	2.77%	-	5.03%

Balance Sheet

	Nov 2015	Nov 2016	Nov 2017	Nov 2018	Nov 2019	Nov 2020	Nov 2021	Nov 2022	Nov 2023	Nov 2024
Total Current Assets+	10.35M	9.01M	12.74M	29.54M	15.39M	18.56M	15.78M	9.61M	9.45M	12.55M
Cash & Short-Term Investments	4.76M	4.12M	6.72M	6.92M	7.45M	10.45M	8.34M	1.72M	980.25K	3.5M
Cash Only	4.15M	3.5M	6.28M	6.04M	6.54M	10.36M	8.26M	1.7M	406.07K	560.96K
Short-Term Investments	610.42K	624.22K	439.32K	875.69K	904.05K	88.48K	75.41K	17.62K	574.18K	2.94M
Accounts Receivable	3.06M	4.05M	5.13M	5.87M	6.1M	6.32M	5.25M	6.04M	6.58M	7.31M
Days Sales Outstanding	52.93	63.96	73.7	73.3	69.95	74.09	66.38	72.72	76.58	83.41
Inventory	475.61K	361.14K	314.57K	16.04M	1.08M	927.32K	921.21K	851.23K	768.88K	657.7K
Days Inventory Outstanding	30.83	22.83	17.07	685.4	39.44	35.05	37.4	35.34	33.24	30.2
Other Current Assets	1.63M	78.45K	206.14K	254.47K	260.4K	244.7K	711.21K	426.88K	512.06K	454.6K
Total Non-Current Assets+	9.14M	10.53M	11.17M	12.85M	27.5M	27.64M	44.88M	55.28M	51.77M	52.12M
Property, Plant & Equipment	879.07K	979.46K	882.38K	1.49M	1.85M	1.94M	4.15M	14.21M	22.03M	22.7M
Fixed Asset Turnover	23.99x	23.61x	28.77x	19.57x	17.23x	16.06x	6.97x	2.14x	1.42x	1.41x
Goodwill	1.78M	0	0	1.94M	1.94M	1.94M	1.94M	1.94M	1.94M	1.94M
Intangible Assets	516.33K	261K	226.42K	1.34M	1.25M	1.53M	16.21M	15.15M	989.12K	921.25K
Long-Term Investments	0	0	0	308K	308K	308K	308K	308K	0	0
Other Non-Current Assets	40.61K	25.5K	28.89K	113.89K	13.07M	11.56M	10.26M	9.92M	6.31M	5.76M
Total Assets+	19.5M	19.54M	23.91M	42.39M	42.89M	46.2M	60.66M	64.89M	61.22M	64.68M
Asset Turnover	1.08x	1.18x	1.06x	0.69x	0.74x	0.67x	0.48x	0.47x	0.51x	0.49x
Asset Growth %	0.91%	0%	0.22%	0.77%	0.01%	0.08%	0.31%	0.07%	-0.06%	0.06%
Total Current Liabilities+	10.42M	13.11M	13.94M	15.43M	15.43M	16.41M	21.07M	19.48M	20.86M	21.6M
Accounts Payable	1.33M	1.49M	1.93M	1.26M	1.37M	957.39K	1.49M	1.61M	3.17M	1.88M
Days Payables Outstanding	86.12	93.89	104.68	53.93	49.79	36.18	60.49	66.64	137.25	86.44
Short-Term Debt	307.42K	0	0	0	3.1M	3.1M	1.9M	2.42M	1.39M	3.69M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	2M	2M	3.1M	0	0	4.96M	1.98M	1.2M	1.42M
Current Ratio	0.99x	0.69x	0.91x	1.91x	1.00x	1.13x	0.75x	0.49x	0.45x	0.58x
Quick Ratio	0.95x	0.66x	0.89x	0.87x	0.93x	1.07x	0.71x	0.45x	0.42x	0.55x
Cash Conversion Cycle	-2.37	-7.1	-13.91	704.77	59.6	72.96	43.3	41.41	-27.43	27.17
Total Non-Current Liabilities+	14.04M	21.84M	22.47M	35.87M	34.41M	32.45M	35.4M	46.93M	51.39M	56.29M
Long-Term Debt	868.95K	0	0	0	0	2.84M	0	8.58M	8.43M	8.31M
Capital Lease Obligations	0	0	0	0	0	23.63K	610.99K	313.3K	851.94K	505.05K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.3M	9.24M	6.72M	15.55M	10.78M	2.38M	3.52M	2.04M	919.23K	922.02K
Total Liabilities	24.46M	34.95M	36.41M	51.3M	49.84M	48.87M	56.48M	66.41M	72.25M	77.89M
Total Debt+	1.18M	9.82M	7.3M	12.94M	8.96M	6.24M	2.82M	11.61M	10.9M	12.93M
Net Debt	-2.98M	6.32M	1.02M	6.9M	2.42M	-4.12M	-5.44M	9.91M	10.49M	12.37M
Debt / Equity	-	-	-	-	-	-	0.67x	-	-	-
Debt / EBITDA	0.37x	13.63x	1.39x	2.35x	1.64x	0.75x	0.53x	1.99x	-	3.26x
Net Debt / EBITDA	-0.94x	8.77x	0.19x	1.25x	0.44x	-0.50x	-1.02x	1.70x	-	3.12x
Interest Coverage	2.25x	0.46x	3.84x	3.35x	2.97x	4.96x	2.91x	2.64x	-9.95x	1.87x
Total Equity+	-4.96M	-15.41M	-12.5M	-8.91M	-6.95M	-2.67M	4.18M	-1.52M	-11.03M	-13.22M
Equity Growth %	0.54%	-2.11%	0.19%	0.29%	0.22%	0.62%	2.57%	-1.36%	-6.24%	-0.2%
Book Value per Share	-0.51	-1.90	-1.63	-1.19	-0.83	-0.33	0.50	-0.18	-1.32	-1.61
Total Shareholders' Equity	-4.96M	-15.41M	-12.5M	-8.91M	-6.95M	-2.67M	4.18M	-1.52M	-11.03M	-13.22M
Common Stock	122.6K	125.04K	129K	135.96K	135.99K	136.34K	146.66K	148.48K	148.49K	148.7K
Retained Earnings	-25.47M	-26.79M	-24.47M	-25.33M	-22.44M	-18.82M	-16.74M	-21.64M	-31.16M	-32.78M
Treasury Stock	-8.32M	-19.12M	-19.57M	-19.57M	-20.56M	-20.56M	-20.81M	-22.63M	-23.43M	-24.86M
Accumulated OCI	169.93K	34.41K	40.87K	340.98K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Nov 2015	Nov 2016	Nov 2017	Nov 2018	Nov 2019	Nov 2020	Nov 2021	Nov 2022	Nov 2023	Nov 2024
Cash from Operations+	4.85M	4.99M	5.72M	5.33M	6.32M	8.47M	7.93M	8.57M	8.92M	6.01M
Operating CF Margin %	0.23%	0.22%	0.23%	0.18%	0.2%	0.27%	0.27%	0.28%	0.28%	0.19%
Operating CF Growth %	2.12%	0.03%	0.15%	-0.07%	0.19%	0.34%	-0.06%	0.08%	0.04%	-0.33%
Net Income	8.11M	-1.32M	2.32M	-854.82K	2.29M	3.62M	2.08M	2.77M	-9.52M	402.1K
Depreciation & Amortization	241.21K	286.65K	230K	317.33K	401.31K	635.98K	1.33M	1.81M	1.71M	1.02M
Stock-Based Compensation	602.98K	1.77M	971.73K	478.38K	397.77K	622.12K	301.62K	461.35K	816.64K	0
Deferred Taxes	-7.37M	-1.91M	-774.81K	2.38M	-1.52M	-1.28M	-1.65M	-1.73M	-6.75M	-309.27K
Other Non-Cash Items	1.4M	4.62M	202.45K	583.8K	2.47M	1.11M	1M	1.01M	16.68M	1.2M
Working Capital Changes	1.87M	1.54M	2.77M	2.43M	2.28M	3.76M	4.86M	4.25M	5.99M	3.7M
Change in Receivables	313.94K	-1.62M	-1.15M	-1.35M	-997.12K	-828.59K	532.79K	-1.72M	6.58M	-2M
Change in Inventory	117.23K	114.47K	46.58K	316.65K	-27.42K	454.94K	210.28K	490K	0	429.18K
Change in Payables	335.71K	329.56K	443.11K	-666.89K	107.46K	-411.72K	532.38K	115.53K	0	-423.72K
Cash from Investing+	-719.35K	-369.73K	93.03K	-11.28M	-690.66K	357.49K	-6.95M	-15.28M	-8.14M	-4.88M
Capital Expenditures	-108.48K	-342.98K	-98.33K	-646.16K	-662.29K	-449.96K	-6.95M	-17.17M	-6.84M	-2.4M
CapEx % of Revenue	0.01%	0.01%	0%	0.02%	0.02%	0.01%	0.24%	0.57%	0.22%	0.08%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-235.5K	-26.75K	191.36K	-136.25K	0	0	0	1.87M	-800K	-1.1M
Cash from Financing+	-3.26M	-5.27M	-3.03M	5.71M	-5.13M	-5M	-3.07M	147.86K	-2.07M	-979.12K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	-7.67M	0	-2.02M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	69.85K	-3.74M	64.7K	1.63K	-39.3K	-1.9M	1.28M	354.77K	-67.5K	304.4K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.74M	4.64M	5.62M	4.69M	5.66M	8.02M	974.92K	-8.6M	1.28M	3.61M
FCF Margin %	0.22%	0.2%	0.22%	0.16%	0.18%	0.26%	0.03%	-0.28%	0.04%	0.11%
FCF Growth %	2.31%	-0.02%	0.21%	-0.17%	0.21%	0.42%	-0.88%	-9.82%	1.15%	1.82%
FCF per Share	0.48	0.57	0.73	0.63	0.67	0.98	0.12	-1.01	0.15	0.44
FCF Conversion (FCF/Net Income)	0.60x	-3.78x	2.47x	-6.24x	2.76x	2.34x	3.80x	3.09x	-0.94x	14.95x
Interest Paid	0	0	0	0	0	0	1.04M	1.26M	1.81M	1.98M
Taxes Paid	0	0	0	0	0	0	3.53M	1.57M	1.82M	2.72M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	274.3%	208.38%	-	-
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	84.69%	-235.27%	-
Gross Margin	73.3%	75.03%	73.51%	70.77%	68.46%	68.99%	68.88%	71.02%	73.07%	75.15%
Net Margin	38.43%	-5.71%	9.12%	-2.93%	7.2%	11.64%	7.21%	9.14%	-30.38%	1.26%
Debt / Equity	-	-	-	-	-	-	0.67x	-	-	-
Interest Coverage	2.25x	0.46x	3.84x	3.35x	2.97x	4.96x	2.91x	2.64x	-9.95x	1.87x
FCF Conversion	0.60x	-3.78x	2.47x	-6.24x	2.76x	2.34x	3.80x	3.09x	-0.94x	14.95x
Revenue Growth	4.79%	9.66%	9.76%	15.1%	8.89%	-2.1%	-7.26%	5.03%	3.32%	2.05%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Processing And Storage Fees	-	-	-	-	-	29.55M	28.4M	29.77M	30.8M	31.55M
Processing And Storage Fees Growth	-	-	-	-	-	-	-3.89%	4.84%	3.44%	2.45%
Public Banking	-	-	-	296.3K	652.2K	726.55K	376.1K	461.63K	481.15K	366.67K
Public Banking Growth	-	-	-	-	120.12%	11.40%	-48.23%	22.74%	4.23%	-23.79%
Product	-	-	-	104.32K	172.4K	244.19K	111.4K	104K	66.46K	67.88K
Product Growth	-	-	-	-	65.25%	41.64%	-54.38%	-6.64%	-36.10%	2.15%
Processing and Storage Fees	-	-	-	27.82M	29.99M	-	-	-	-	-
Processing and Storage Fees Growth	-	-	-	-	7.82%	-	-	-	-	-
Umbilical Cord Blood And Cord Tissue Stem Cell Service	20.62M	22.78M	24.94M	-	-	-	-	-	-	-
Umbilical Cord Blood And Cord Tissue Stem Cell Service Growth	-	10.46%	9.50%	-	-	-	-	-	-	-
Prepacyte-CB	471.29K	350.13K	442.19K	-	-	-	-	-	-	-
Prepacyte-CB Growth	-	-25.71%	26.29%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
FLORIDA	-	-	-	-	-	-	1M	1M	1M	1M
FLORIDA Growth	-	-	-	-	-	-	-	0.00%	0.00%	0.00%
ILLINOIS	-	-	-	1M	1M	-	1M	-	-	-
ILLINOIS Growth	-	-	-	-	0.00%	-	-	-	-	-
INDIA	1M	1.01M	1M	-	-	629.7K	-	-	-	-
INDIA Growth	-	0.63%	-0.32%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Cryo-Cell International, Inc. (CCEL) has a price-to-earnings (P/E) ratio of 68.4x. This suggests investors expect higher future growth.

Growth & Financials

Cryo-Cell International, Inc. (CCEL) reported $31.7M in revenue for fiscal year 2024. This represents a 77% increase from $17.9M in 2011.

Cryo-Cell International, Inc. (CCEL) grew revenue by 2.0% over the past year. Growth has been modest.

Yes, Cryo-Cell International, Inc. (CCEL) is profitable, generating $0.4M in net income for fiscal year 2024 (1.3% net margin).

Dividend & Returns

Yes, Cryo-Cell International, Inc. (CCEL) pays a dividend with a yield of 7.19%. This makes it attractive for income-focused investors.

Cryo-Cell International, Inc. (CCEL) generated $6.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...